Huadong Medicine subsidiary gets clinical trial nod for DR30206

Huadong Medicine (SZSE:000963) announced that its controlling subsidiary, Zhejiang Doer Biologics, has received approval from China's National Medical Products Administration (NMPA) for clinical trials of its injectable drug, DR30206. The drug, classified as a Class 1 therapeutic biological product, is intended for combination therapy in patients with advanced or metastatic digestive tract tumors. DR30206 is an antibody fusion protein targeting PD-L1, VEGF, and TGF-β. Huadong Medicine noted that the approval marks a significant step in the development of this novel drug. While the company acknowledges the high risks and long development cycles associated with pharmaceutical R&D, it commits to adhering to regulatory requirements and disclosing progress updates while reminding investors to be mindful of investment risks. The first clinical trial of DR30206 was approved in June 2023.